$TXG
10X Genomics Inc Stock $txg

$txg Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000177078722000015 Filed on February 18, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$143.5M	$490.5M	$112.2M
YoY Change	27.92%	64.13%	49.03%
Cost Of Revenue	$27.60M	$74.09M	$18.90M
YoY Change	46.02%	26.72%	13.86%
Gross Profit	$115.9M	$416.4M	$93.30M
YoY Change	24.26%	73.23%	58.92%
Gross Profit Margin	80.77%	84.89%	83.16%
Selling, General & Admin	$69.88M	$257.6M	$55.10M
YoY Change	26.82%	27.3%	42.01%
% of Gross Profit	60.27%	61.85%	59.06%
Research & Development	$61.89M	$211.8M	$446.6M
YoY Change	-86.14%	71.63%	1500.72%
% of Gross Profit	53.38%	50.85%	478.67%
Depreciation & Amortization	$5.781M	$21.12M	$3.920M
YoY Change	47.47%	50.71%	37.54%
% of Gross Profit	4.99%	5.07%	4.2%
Operating Expenses	$131.8M	$468.7M	$502.0M
YoY Change	-73.75%	-39.49%	651.5%
Operating Profit	-$15.83M	-$52.25M	-$408.7M
YoY Change	-96.13%	-90.22%	4950.04%
Interest Expense	-$168.0K	$866.0K	-$300.0K
YoY Change	-44.0%	-48.51%	-137.5%
% of Operating Profit
Other Income/Expense, Net	$5.000K	-$1.462M	$1.200M
YoY Change	-99.58%	337.72%	500.0%
Pretax Income	-$15.99M	-$53.72M	-$408.6M
YoY Change	-96.09%	-89.95%	5737.14%
Income Tax	$2.456M	$4.508M	$7.000M
% Of Pretax Income
Net Earnings	-$18.45M	-$58.22M	-$415.6M
YoY Change	-95.56%	-89.27%	5725.62%
Net Earnings / Revenue	-12.85%	-11.87%	-370.41%
Basic Earnings Per Share		-$0.53
Diluted Earnings Per Share	-$164.9K	-$0.53	-$3.870M
COMMON SHARES
Basic Shares Outstanding		110.3M shares
Diluted Shares Outstanding		110.3M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$587.4M	$587.4M	$663.6M
YoY Change	-11.48%	-11.48%	56.44%
Cash & Equivalents	$587.4M	$587.4M	$663.6M
Short-Term Investments	$0.00
Other Short-Term Assets	$14.92M	$14.92M	$29.60M
YoY Change	-49.58%	-49.58%	270.0%
Inventory	$59.97M	$59.97M	$29.96M
Prepaid Expenses
Receivables	$85.25M	$85.25M	$51.21M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$747.6M	$747.6M	$774.4M
YoY Change	-3.46%	-3.46%	61.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$169.5M	$230.4M	$72.84M
YoY Change	132.69%	92.33%	49.2%
Goodwill	$4.511M		$0.00
YoY Change
Intangibles	$25.40M		$22.35M
YoY Change	13.61%
Long-Term Investments
YoY Change
Other Assets	$3.319M	$10.92M	$4.324M
YoY Change	-23.24%	-14.71%	-81.93%
Total Long-Term Assets	$271.2M	$271.2M	$155.0M
YoY Change	75.02%	75.1%	23.9%
TOTAL ASSETS
Total Short-Term Assets	$747.6M	$747.6M	$774.4M
Total Long-Term Assets	$271.2M	$271.2M	$155.0M
Total Assets	$1.019B	$1.019B	$929.3M
YoY Change	9.63%	9.63%	53.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.35M	$17.35M	$4.709M
YoY Change	268.46%	269.17%	-63.85%
Accrued Expenses	$75.82M	$75.82M	$92.30M
YoY Change	-17.85%	-17.85%	207.67%
Deferred Revenue	$5.340M		$4.472M
YoY Change	19.41%		35.64%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$110.4M	$110.4M	$118.1M
YoY Change	-6.58%	-6.56%	87.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$8.240M	$90.90M	$3.930M
YoY Change	109.67%	26.08%	104.16%
Total Long-Term Liabilities	$8.240M	$90.90M	$3.930M
YoY Change	109.67%	26.08%	-81.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$110.4M	$110.4M	$118.1M
Total Long-Term Liabilities	$8.240M	$90.90M	$3.930M
Total Liabilities	$201.3M	$201.3M	$190.3M
YoY Change	5.78%	5.76%	2.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$863.3M		-$805.1M
YoY Change	7.23%		206.86%
Common Stock	$1.681B		$1.544B
YoY Change	8.85%		126.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$817.6M	$817.6M	$739.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.019B	$1.019B	$929.3M
YoY Change	9.63%	9.63%	53.38%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$18.45M	-$58.22M	-$415.6M
YoY Change	-95.56%	-89.27%	5725.62%
Depreciation, Depletion And Amortization	$5.781M	$21.12M	$3.920M
YoY Change	47.47%	50.71%	37.54%
Cash From Operating Activities	$5.805M	-$21.37M	-$130.2M
YoY Change	-104.46%	-90.19%	-2042.99%
INVESTING ACTIVITIES
Capital Expenditures	-$27.62M	$101.3M	-$22.26M
YoY Change	24.07%	176.22%	238.3%
Acquisitions		$5.451M
YoY Change
Other Investing Activities	$0.00	-$5.451M
YoY Change
Cash From Investing Activities	-$27.62M	-$106.7M	-$22.26M
YoY Change	24.07%	177.98%	238.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	8.903M	$35.30M	7.710M
YoY Change	15.47%	-92.47%	-794.59%
NET CHANGE
Cash From Operating Activities	5.805M	-$21.37M	-130.2M
Cash From Investing Activities	-27.62M	-$106.7M	-22.26M
Cash From Financing Activities	8.903M	$35.30M	7.710M
Net Change In Cash	-12.91M	-$92.57M	-144.7M
YoY Change	-91.08%	-143.63%	14519.19%
FREE CASH FLOW
Cash From Operating Activities	$5.805M	-$21.37M	-$130.2M
Capital Expenditures	-$27.62M	$101.3M	-$22.26M
Free Cash Flow	$33.42M	-$122.7M	-$107.9M
YoY Change	-130.97%	-51.82%	-912.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001770787
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39035
CY2021	dei	Entity Registrant Name EntityRegistrantName	10x Genomics, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5614458
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	6230 Stoneridge Mall Road
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
CY2021	dei	City Area Code CityAreaCode	(925)
CY2021	dei	Local Phone Number LocalPhoneNumber	401-7300
CY2021	dei	Security12b Title Security12bTitle	Class A common stock, par value $0.00001 per share
CY2021	dei	Trading Symbol TradingSymbol	TXG
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	18700000000	USD
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	587447000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	663603000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1028000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16567000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85254000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51208000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	59966000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	29959000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13896000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13029000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	747591000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	774366000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	169492000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72840000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	7598000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8474000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	60918000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46983000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	4511000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	0	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25397000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22354000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3319000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4324000	USD
CY2021Q4	us-gaap	Assets Assets	1018826000	USD
CY2020Q4	us-gaap	Assets Assets	929341000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17351000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4709000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31626000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15383000	USD
CY2021Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	50909000	USD
CY2020Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	43453000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5340000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4472000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5131000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5936000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	44173000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	110357000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118126000	USD
CY2021Q4	txg	License Fees Accrued Noncurrent LicenseFeesAccruedNoncurrent	5814000	USD
CY2020Q4	txg	License Fees Accrued Noncurrent LicenseFeesAccruedNoncurrent	11171000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76847000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57042000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8240000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3930000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	201258000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	190269000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	817568000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112514977	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112514977	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108485909	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108485909	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1680865000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1544218000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-863321000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805098000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	739072000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1018826000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	929341000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	490490000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245893000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	74091000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	58468000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	61033000	USD
CY2021	us-gaap	Gross Profit GrossProfit	416399000	USD
CY2020	us-gaap	Gross Profit GrossProfit	240377000	USD
CY2019	us-gaap	Gross Profit GrossProfit	184860000	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	211752000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	123375000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	83097000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	100000	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	447548000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	257560000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	202326000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	130834000	USD
CY2021	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	-660000	USD
CY2020	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	1270000	USD
CY2019	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	1502000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	468652000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	774519000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	215433000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-52253000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-534142000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-30573000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	206000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1532000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2805000	USD
CY2021	us-gaap	Interest Expense InterestExpense	866000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1682000	USD
CY2019	us-gaap	Interest Expense InterestExpense	3079000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-802000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1337000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-186000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1521000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1462000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-334000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-460000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53715000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-534476000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31033000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4508000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8255000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58223000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58223000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	72000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58151000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-542735000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31260000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.37
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.37
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	110347937	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110347937	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101151675	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101151675	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39091366	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39091366	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-219987000	USD
CY2019	txg	Adjustments To Additional Paid In Capital Vesting Of Shares Including Early Exercise Of Options AdjustmentsToAdditionalPaidInCapitalVestingOfSharesIncludingEarlyExerciseOfOptions	494000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13333000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	420083000	USD
CY2020	txg	Adjustments To Additional Paid In Capital Vesting Of Shares Including Early Exercise Of Options AdjustmentsToAdditionalPaidInCapitalVestingOfSharesIncludingEarlyExerciseOfOptions	247000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49467000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	739072000	USD
CY2021	txg	Adjustments To Additional Paid In Capital Vesting Of Shares Including Early Exercise Of Options AdjustmentsToAdditionalPaidInCapitalVestingOfSharesIncludingEarlyExerciseOfOptions	154000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	96168000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58223000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	72000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	817568000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58223000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58223000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-542731000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-31251000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21118000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14012000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7066000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	95962000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	48626000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	13333000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-79000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-614000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1521000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	7136000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5009000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	306000000	USD
CY2019	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	17000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	101000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34041000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17847000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5284000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	30132000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14601000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6699000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1053000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5265000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3535000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1045000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2686000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	251000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11084000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7770000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4901000	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	16337000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2936000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5292000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1535000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2023000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	634000	USD
CY2021	txg	Increase Decrease In Accrued Contingent Liabilities IncreaseDecreaseInAccruedContingentLiabilities	-44173000	USD
CY2020	txg	Increase Decrease In Accrued Contingent Liabilities IncreaseDecreaseInAccruedContingentLiabilities	-24485000	USD
CY2019	txg	Increase Decrease In Accrued Contingent Liabilities IncreaseDecreaseInAccruedContingentLiabilities	30658000	USD
CY2021	txg	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	-873000	USD
CY2020	txg	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	25917000	USD
CY2019	txg	Increase Decrease In Accrued Liabilities And Other Current Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities	5771000	USD
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	12730000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2469000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4832000	USD
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4705000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3771000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	547000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21373000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-217898000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34627000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101278000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36666000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42742000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5451000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1728000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-106729000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38394000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42767000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	31256000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	11000000	USD
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	11000000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5028000	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5848000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	482267000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	410824000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	40325000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23743000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3766000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35297000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	468906000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	414590000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-463000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-45000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92571000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	212151000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	406405000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	476493000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70088000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	596073000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	476493000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1222000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1670000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2250000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8660000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	280000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	22000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16972000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2983000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4492000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	21284000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13562000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	1500000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	243244000	USD
CY2021	txg	Purchase Of Technology Licenses Under Financing Arrangement PurchaseOfTechnologyLicensesUnderFinancingArrangement	0	USD
CY2020	txg	Purchase Of Technology Licenses Under Financing Arrangement PurchaseOfTechnologyLicensesUnderFinancingArrangement	0	USD
CY2019	txg	Purchase Of Technology Licenses Under Financing Arrangement PurchaseOfTechnologyLicensesUnderFinancingArrangement	22099000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72840000	USD
CY2020	us-gaap	Depreciation Depreciation	12300000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, accounting for asset and business acquisitions and the valuation of stock-based compensation awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation may be affected. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.</span></div>
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	587447000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	663603000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	424166000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	8626000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	25041000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	52327000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	596073000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	476493000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents held with large financial institutions in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of these financial institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced material credit losses to date. For the years ended December 31, 2021, 2020, and 2019, no single customer represented more than 10% of revenue. As of December 31, 2021, one of the Company's distributors accounted for 11% of the Company’s outstanding accounts receivable. No other customer or distributor represented more than 10% of the Company’s outstanding accounts receivable as of December 31, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all the Company’s long-lived assets are located in the United States.</span></div>
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1300000	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	4700000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1900000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1500000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-900000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	31954000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	9930000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14052000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9312000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13960000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10717000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	59966000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	29959000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	218513000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	103342000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	49021000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30502000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	169492000	USD
CY2021	us-gaap	Depreciation Depreciation	18500000	USD
CY2019	us-gaap	Depreciation Depreciation	6700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	30281000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4884000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25397000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24641000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2287000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22354000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2535000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2506000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2378000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2214000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2024000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	13740000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25397000	USD
CY2021Q4	txg	Accrued Payroll And Related Costs AccruedPayrollAndRelatedCosts	3978000	USD
CY2020Q4	txg	Accrued Payroll And Related Costs AccruedPayrollAndRelatedCosts	2506000	USD
CY2021Q4	txg	Employee Stock Purchase Program Liability EmployeeStockPurchaseProgramLiability	1693000	USD
CY2020Q4	txg	Employee Stock Purchase Program Liability EmployeeStockPurchaseProgramLiability	1258000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	16558000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5058000	USD
CY2021Q4	txg	Accrued Commissions Current AccruedCommissionsCurrent	3417000	USD
CY2020Q4	txg	Accrued Commissions Current AccruedCommissionsCurrent	3038000	USD
CY2021Q4	txg	Accrued Acquisition Related Compensation Current AccruedAcquisitionRelatedCompensationCurrent	4430000	USD
CY2020Q4	txg	Accrued Acquisition Related Compensation Current AccruedAcquisitionRelatedCompensationCurrent	2213000	USD
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1172000	USD
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1035000	USD
CY2021Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	378000	USD
CY2020Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	275000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31626000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15383000	USD
CY2021Q4	txg	Accrued Legal And Related Expenses Current AccruedLegalAndRelatedExpensesCurrent	2425000	USD
CY2020Q4	txg	Accrued Legal And Related Expenses Current AccruedLegalAndRelatedExpensesCurrent	5704000	USD
CY2021Q4	txg	Accrued License Fees Current AccruedLicenseFeesCurrent	6214000	USD
CY2020Q4	txg	Accrued License Fees Current AccruedLicenseFeesCurrent	6198000	USD
CY2021Q4	txg	Accrued Purchase Consideration Current AccruedPurchaseConsiderationCurrent	0	USD
CY2020Q4	txg	Accrued Purchase Consideration Current AccruedPurchaseConsiderationCurrent	4146000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4415000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3160000	USD
CY2021Q4	txg	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	15361000	USD
CY2020Q4	txg	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	2983000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	8593000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3137000	USD
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	994000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	399000	USD
CY2021Q4	txg	Customer Deposits Liability Current CustomerDepositsLiabilityCurrent	954000	USD
CY2020Q4	txg	Customer Deposits Liability Current CustomerDepositsLiabilityCurrent	1727000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4622000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8649000	USD
CY2021Q4	txg	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	2056000	USD
CY2020Q4	txg	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	1506000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5275000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5844000	USD
CY2021Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	50909000	USD
CY2020Q4	txg	Accrued Expensesand Other Liabilities Current AccruedExpensesandOtherLiabilitiesCurrent	43453000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	399000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	467000	USD
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2934000	USD
CY2020	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	796000	USD
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2339000	USD
CY2020	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	864000	USD
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	994000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	399000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7700000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5300000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7700000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6200000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6154000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4131000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4101000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3295000	USD
CY2021	txg	Contract With Customer Liability Increase Excluding Revenue Recognized ContractWithCustomerLiabilityIncreaseExcludingRevenueRecognized	5635000	USD
CY2020	txg	Contract With Customer Liability Increase Excluding Revenue Recognized ContractWithCustomerLiabilityIncreaseExcludingRevenueRecognized	5318000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7688000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6154000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	490490000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245893000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	490490000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	298845000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	245893000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53715000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-534476000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31033000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	98000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5148000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	8173000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	126000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5198000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8173000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	224000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-690000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	82000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-6000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-690000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	82000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4508000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8255000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4500000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8300000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-11280000	USD
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-112240000	USD
CY2019	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-6517000	USD
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-20136000	USD
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-16653000	USD
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-2958000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	11836000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	9453000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2684000	USD
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	142000	USD
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	41253000	USD
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	101000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-78852000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-52070000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1032000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	126386000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	99034000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	10783000	USD
CY2021	txg	Income Tax Reconciliation Acquisition Related Expenses IncomeTaxReconciliationAcquisitionRelatedExpenses	-793000	USD
CY2020	txg	Income Tax Reconciliation Acquisition Related Expenses IncomeTaxReconciliationAcquisitionRelatedExpenses	93407000	USD
CY2019	txg	Income Tax Reconciliation Acquisition Related Expenses IncomeTaxReconciliationAcquisitionRelatedExpenses	116000	USD
CY2021	txg	Effective Income Tax Rate Reconciliation Change Tax Status Amount EffectiveIncomeTaxRateReconciliationChangeTaxStatusAmount	0	USD
CY2020	txg	Effective Income Tax Rate Reconciliation Change Tax Status Amount EffectiveIncomeTaxRateReconciliationChangeTaxStatusAmount	-34731000	USD
CY2019	txg	Effective Income Tax Rate Reconciliation Change Tax Status Amount EffectiveIncomeTaxRateReconciliationChangeTaxStatusAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	877000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-292000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	345000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4508000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8255000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	218000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	195953000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	90562000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	54117000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	31908000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	7868000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	14392000	USD
CY2021Q4	txg	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	19697000	USD
CY2020Q4	txg	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	14192000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	40716000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	43261000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12261000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6601000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	330612000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	200916000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	313194000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	186853000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17418000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14063000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4189000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3750000	USD
CY2021Q4	txg	Deferred Tax Liability Operating Right Of Use Assets DeferredTaxLiabilityOperatingRightOfUseAssets	13745000	USD
CY2020Q4	txg	Deferred Tax Liability Operating Right Of Use Assets DeferredTaxLiabilityOperatingRightOfUseAssets	10388000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17934000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14138000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	516000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	75000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	126300000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	120400000	USD
CY2013Q4	txg	Operating Loss Carryforwards Limitation Amount OperatingLossCarryforwardsLimitationAmount	4800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14657000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6410000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	252000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	311000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	9354000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8558000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23759000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14657000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14700000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1500000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	600000	USD
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	200000	USD
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	200000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	500000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	10500000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	8400000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	600000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	400000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6200000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	7100000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9376000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12237000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12203000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11225000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11678000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	48099000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	104818000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22840000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	81978000	USD
CY2021Q4	txg	Operating Lease Current Liability OperatingLeaseCurrentLiability	5131000	USD
CY2021Q4	txg	Operating Lease Noncurrent Liability OperatingLeaseNoncurrentLiability	76847000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2021Q4	txg	Shares Of Capital Stock Authorized SharesOfCapitalStockAuthorized	1200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112514977	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112514977	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108485909	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108485909	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	823947	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	80.97
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	970033	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	179.95
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	382380	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	114.11
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	113356	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	123.21
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1298244	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	141.48
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	95962000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48626000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13333000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9543116	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13000964	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16112652	shares

Files In Submission

Name	View Source	Status
0001770787-22-000015-index-headers.html	Edgar Link	pending
0001770787-22-000015-index.html	Edgar Link	pending
0001770787-22-000015.txt	Edgar Link	pending
0001770787-22-000015-xbrl.zip	Edgar Link	pending
a231_ey10kconsent.htm	Edgar Link	pending
exhibit1029.htm	Edgar Link	pending
exhibit42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
txg-20211231.htm	Edgar Link	pending
txg-20211231.xsd	Edgar Link	pending
txg-20211231xex311.htm	Edgar Link	pending
txg-20211231xex312.htm	Edgar Link	pending
txg-20211231xex321.htm	Edgar Link	pending
txg-20211231xex322.htm	Edgar Link	pending
txg-20211231_cal.xml	Edgar Link	unprocessable
txg-20211231_def.xml	Edgar Link	unprocessable
txg-20211231_g1.jpg	Edgar Link	pending
txg-20211231_g10.jpg	Edgar Link	pending
txg-20211231_g11.jpg	Edgar Link	pending
txg-20211231_g2.jpg	Edgar Link	pending
txg-20211231_g3.jpg	Edgar Link	pending
txg-20211231_g4.jpg	Edgar Link	pending
txg-20211231_g5.jpg	Edgar Link	pending
txg-20211231_g6.jpg	Edgar Link	pending
txg-20211231_g7.jpg	Edgar Link	pending
txg-20211231_g8.jpg	Edgar Link	pending
txg-20211231_g9.jpg	Edgar Link	pending
txg-20211231_htm.xml	Edgar Link	completed
txg-20211231_lab.xml	Edgar Link	unprocessable
txg-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TXG
10X Genomics Inc Stock $txg

2021 Q4 Form 10-K Financial Statement

#000177078722000015 Filed on February 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TXG 10X Genomics Inc Stock $txg

2021 Q4 Form 10-K Financial Statement

#000177078722000015 Filed on February 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TXG
10X Genomics Inc Stock $txg